Danaher Corporation (DHR) Stake Lowered by Eads & Heald Investment Counsel

Eads & Heald Investment Counsel trimmed its position in shares of Danaher Corporation (NYSE:DHR) by 1.9% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,913 shares of the conglomerate’s stock after selling 405 shares during the period. Eads & Heald Investment Counsel’s holdings in Danaher Corporation were worth $1,765,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in DHR. BlackRock Inc. raised its position in shares of Danaher Corporation by 2,530.9% during the 1st quarter. BlackRock Inc. now owns 37,967,922 shares of the conglomerate’s stock valued at $3,247,398,000 after purchasing an additional 36,524,795 shares during the period. Flossbach Von Storch AG raised its position in shares of Danaher Corporation by 44.7% during the 2nd quarter. Flossbach Von Storch AG now owns 5,782,019 shares of the conglomerate’s stock valued at $487,945,000 after purchasing an additional 1,785,810 shares during the period. Vanguard Group Inc. raised its position in shares of Danaher Corporation by 3.9% during the 1st quarter. Vanguard Group Inc. now owns 40,967,631 shares of the conglomerate’s stock valued at $3,503,962,000 after purchasing an additional 1,530,015 shares during the period. MARSHALL WACE ASIA Ltd bought a new stake in shares of Danaher Corporation during the 1st quarter valued at $116,462,000. Finally, Marshall Wace North America L.P. bought a new stake in shares of Danaher Corporation during the 1st quarter valued at $116,462,000. Hedge funds and other institutional investors own 75.75% of the company’s stock.

DHR has been the topic of several recent analyst reports. Janney Montgomery Scott downgraded shares of Danaher Corporation from a “buy” rating to a “neutral” rating in a research report on Wednesday, June 7th. BidaskClub downgraded shares of Danaher Corporation from a “hold” rating to a “sell” rating in a research report on Saturday, July 8th. Wells Fargo & Company restated a “market perform” rating on shares of Danaher Corporation in a research report on Saturday, July 22nd. Citigroup Inc. set a $96.00 target price on shares of Danaher Corporation and gave the company a “buy” rating in a research note on Friday, July 21st. Finally, Zacks Investment Research cut shares of Danaher Corporation from a “hold” rating to a “sell” rating in a research note on Monday, June 19th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $92.72.

COPYRIGHT VIOLATION NOTICE: “Danaher Corporation (DHR) Stake Lowered by Eads & Heald Investment Counsel” was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://sportsperspectives.com/2017/09/13/danaher-corporation-dhr-stake-lowered-by-eads-heald-investment-counsel.html.

Danaher Corporation (NYSE DHR) opened at 87.27 on Wednesday. The firm has a 50 day moving average of $81.99 and a 200-day moving average of $84.14. Danaher Corporation has a 52 week low of $75.71 and a 52 week high of $88.01. The stock has a market capitalization of $60.63 billion, a PE ratio of 27.86 and a beta of 1.03.

Danaher Corporation (NYSE:DHR) last released its earnings results on Thursday, July 20th. The conglomerate reported $0.99 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.97 by $0.02. Danaher Corporation had a net margin of 12.63% and a return on equity of 11.15%. The business had revenue of $4.51 billion during the quarter, compared to analyst estimates of $4.50 billion. During the same quarter in the prior year, the firm earned $0.90 earnings per share. The company’s revenue for the quarter was up 6.3% compared to the same quarter last year. On average, equities analysts predict that Danaher Corporation will post $3.95 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Friday, September 29th will be issued a dividend of $0.14 per share. This represents a $0.56 dividend on an annualized basis and a dividend yield of 0.64%. Danaher Corporation’s payout ratio is 17.83%.

In other news, insider William King sold 43,688 shares of the company’s stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $82.86, for a total transaction of $3,619,987.68. Following the completion of the sale, the insider now owns 45,748 shares of the company’s stock, valued at $3,790,679.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Thomas Patrick Joyce, Jr. sold 9,772 shares of the company’s stock in a transaction on Monday, July 31st. The stock was sold at an average price of $81.78, for a total transaction of $799,154.16. Following the sale, the insider now directly owns 155,520 shares of the company’s stock, valued at approximately $12,718,425.60. The disclosure for this sale can be found here. Insiders have sold 71,496 shares of company stock valued at $5,916,223 in the last ninety days. Insiders own 12.20% of the company’s stock.

Danaher Corporation Company Profile

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Institutional Ownership by Quarter for Danaher Corporation (NYSE:DHR)

Receive News & Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply